Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 13, 2016, Pages E1944-E1952

  Ren, Qian ^a   Ma, Min ^a   Ishima, Tamaki ^a   Morisseau, Christophe ^b   Yang, Jun ^b   Wagner, Karen M ^b   Zhang, Ji Chun ^a   Yang, Chun ^a   Yao, Wei ^a   Dong, Chao ^a   Han, Mei ^a   Hammock, Bruce D ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain derived neurotrophic factor; Depression; Epoxyeicosatrienoic acid soluble epoxide hydrolase; Resilience

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; ENZYME INHIBITOR; EPOXIDE HYDROLASE; POSTSYNAPTIC DENSITY PROTEIN 95; SOLUBLE EPOXIDE HYDROLASE; TPPU; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 1-TRIFLUOROMETHOXYPHENYL-3-(1-PROPIONYLPIPERIDINE-4-YL)UREA; ANTIDEPRESSANT AGENT; CARBANILAMIDE DERIVATIVE; OXYLIPIN; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BRAIN CORTEX; CONTROLLED STUDY; COPING BEHAVIOR; DEPRESSION; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME ACTIVITY; HIPPOCAMPUS; INFLAMMATION; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOCIAL DEFEAT STRESS; SOCIAL STRESS; SYNAPTOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; C57BL MOUSE; COMPLICATION; DISEASE MODEL; GENETICS; HUMAN; KNOCKOUT MOUSE; MENTAL STRESS; METABOLISM; MUTANT RAT STRAIN; SOCIAL BEHAVIOR;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; INFLAMMATION; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXYLIPINS; PHENYLUREA COMPOUNDS; PIPERIDINES; RATS, MUTANT STRAINS; SOCIAL BEHAVIOR; STRESS, PSYCHOLOGICAL;

EID: 84962090243     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1601532113     Document Type: Article

References (69)

1. World Health Organization (2012) Depression. Fact sheet No. 369/October 2012. Available at www.who.int/mediacentre/factsheets/fs369/en. Accessed February 24, 2016.
2. Steinert C, Hofmann M, Kruse J, Leichsenring F (2014) Relapse rates after psychotherapy for depression - Stable long-term effects? A meta-analysis. J Affect Disord 168: 107-118.
3. Biesheuvel-Leliefeld KE, et al. (2015) Effectiveness of psychological interventions in preventing recurrence of depressive disorder: Meta-analysis and meta-regression. J Affect Disord 174: 400-410.
4. Guidi J, Tomba E, Fava GA (2016) The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: A meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry 173(2): 128-137.
5. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 9(1): 46-56.
6. Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65(9): 732-741.
7. Raison CL, Lowry CA, Rook GA (2010) Inflammation, sanitation, and consternation: Loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry 67(12): 1211-1224.
8. Hashimoto K (2015) Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci 16(4): 7796-7801.
9. Gold PW (2015) The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry 20(1): 32-47.
10. Dowlati Y, et al. (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67(5): 446-457.
11. Young JJ, Bruno D, Pomara N (2014) A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord 169: 15-20.
12. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M (2015) Cumulative metaanalysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 49: 206-215.
13. Strawbridge R, et al. (2015) Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol 25(10): 1532-1543.
14. Dean B, Tawadros N, Scarr E, Gibbons AS (2010) Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Disord 120(1-3): 245-248.
15. Shelton RC, et al. (2011) Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 16(7): 751-762.
16. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY (2014) Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 48: 79-85.
17. Köhler O, et al. (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71(12): 1381-1391.
18. Morisseau C, Hammock BD (2005) Epoxide hydrolases: Mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 45: 311-333.
19. Imig JD, Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8(10): 794-805.
20. Morisseau C, Hammock BD (2013) Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol 53: 37-58.
21. Harris TR, Hammock BD (2013) Soluble epoxide hydrolase: Gene structure, expression and deletion. Gene 526(2): 61-74.
22. Wagner K, Vito S, Inceoglu B, Hammock BD (2014) The role of long chain fatty acids and their epoxide metabolites in nociceptive signaling. Prostaglandins Other Lipid Mediat 113-115: 2-12.
23. López-Vicario C, et al. (2015) Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides. Proc Natl Acad Sci USA 112(2): 536-541.
24. Shih PB, et al. (2015) Dysregulation of soluble epoxide hydrolase and lipidomic profiles in anorexia nervosa. Mol Psychiatry, 10.1038/mp.2015.26.
25. Nestler EJ, et al. (2002) Neurobiology of depression. Neuron 34(1): 13-25.
26. Hashimoto K, Shimizu E, Iyo M (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 45(2): 104-114.
27. Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59(12): 1116-1127.
28. Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions. Psychiatry Clin Neurosci 64(4): 341-357.
29. Hashimoto K (2013) Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression. Prog Neurobiol 100: 15-29.
30. Björkholm C, Monteggia LM (2016) BDNF - A key transducer of antidepressant effects. Neuropharmacology 102: 72-79.
31. Rose TE, et al. (2010) 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J Med Chem 53(19): 7067-7075.
32. Liu JY, et al. (2013) Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models. Eur J Pharm Sci 48(4-5): 619-627.
33. Sirish P, et al. (2013) Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis. Proc Natl Acad Sci USA 110(14): 5618-5623.
34. Abdu E, et al. (2011) Epoxyeicosatrienoic acids enhance axonal growth in primary sensory and cortical neuronal cell cultures. J Neurochem 117(4): 632-642.
35. Ostermann AI, et al. (2015) Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)rea (TPPU): Bioavailability, resulting drug levels and modulation of oxylipin pattern. Prostaglandins Other Lipid Mediat 121(Part A): 131-137.
36. Zhang JC, et al. (2015) Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol 18(4): pyu077.
37. Zhang JC, et al. (2015) Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 anti-depressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) 232(23): 4325-4335.
38. Yang C, Shirayama Y, Zhang JC, Ren Q, Hashimoto K (2015) Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress. Int J Neuropsychopharmacol 18(7): pyu121.
39. Yang C, et al. (2015) R-ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5: e632.
40. Shirayama Y, et al. (2015) Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist. Eur Neuropsychopharmacol 25(12): 2449-2458.
41. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH (2000) The Stanley Foundation Brain Collection and Neuropathology Consortium. Schizophr Res 44(2): 151-155.
42. Berton O, et al. (2006) Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311(5762): 864-868.
43. Krishnan V, Nestler EJ (2010) Linking molecules to mood: New insight into the biology of depression. Am J Psychiatry 167(11): 1305-1320.
44. Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond. Biol Psychiatry 73(12): 1133-1141.
45. Monteggia LM, Zarate C, Jr (2015) Antidepressant actions of ketamine: From molecular mechanisms to clinical practice. Curr Opin Neurobiol 30: 139-143.
46. Newport DJ, et al.; APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) Ketamine and other NMDA antagonusts: Early clinical trials and possible mechanisms in depression. Am J Psychiatry 172(10): 950-966.
47. Munkholm K, Braüner JV, Kessing LV, Vinberg M (2013) Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. J Psychiatr Res 47(9): 1119-1133.
48. Dargél AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M (2015) C-reactive protein alterations in bipolar disorder: A meta-analysis. J Clin Psychiatry 76(2): 142-150.
49. Potvin S, et al. (2008) Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol Psychiatry 63(8): 801-808.
50. Fernandes BS, et al. (2015) C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: Meta-analysis and implications. Mol Psychiatry, 10.1038/mp.2015.87.
51. Hodes GE, et al. (2014) Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci USA 111(45): 16136-16141.
52. Yang C, Shirayama Y, Zhang JC, Ren Q, Hashimoto K (2015) Peripheral interleukin-6 promotes resilience versus susceptibility to inescapable electric stress. Acta Neuropsychiatr 27(5): 312-316.
53. Yang C, Hashimoto K (2015) Peripheral IL-6 signaling: A promising therapeutic target for depression? Expert Opin Investig Drugs 24(7): 989-990.
54. Yuan L, et al. (2015) 14,15-epoxyeicosatrienoic acid promotes production of BDNF from astrocytes and exerts neuroprotective effects during ischemic injury. Neuropathol Appl Neurobiol, 10.1111/nan.12291.
55. Forte A, et al. (2015) Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord 178: 71-78.
56. Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ (2015) Prevention of relapse and recurrence in adults with major depressive disorder: Systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol 18: pyv076.
57. Sinal CJ, et al. (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275(51): 40504-40510.
58. National Institutes of Health (2011) Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD), 8th Ed.
59. Hashimoto K, Ishima T (2010) A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: Translation initiation [corrected] factor eIF4AI. PLoS One 5(11): e15430
60. erratum in PLoS One (2010) 5(12): 10.1371/annotation/afc0a9a2-01c0-4e58-8d69-e0ed4ff953fa.
61. Ishima T, Hashimoto K (2012) Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: The role of sigma-1 and IP3 receptors. PLoS One 7(5): e37989.
62. 2A receptors. Eur Neuropsychopharmacol 25(4): 505-511.
63. Golden SA, Covington HE, 3rd, Berton O, Russo SJ (2011) A standardized protocol for repeated social defeat stress in mice. Nat Protoc 6(8): 1183-1191.
64. Zhao T, et al. (2013) Effects of chronic social defeat stress on behavior and choline acetyltransferase, 78-kDa glucose-regulated protein, and CCAAT/enhancer-binding protein (C/EBP) homologous protein in adult mice. Psychopharmacology (Berl) 228(2): 217-230.
65. Inceoglu B, et al. (2013) Epoxy fatty acids and inhibition of the soluble epoxide hydrolase selectively modulate GABA mediated neurotransmission to delay onset of seizures. PLoS One 8(12): e80922.
66. Borhan B, Mebrahtu T, Nazarian S, Kurth MJ, Hammock BD (1995) Improved radiolabeled substrates for soluble epoxide hydrolase. Anal Biochem 231(1): 188-200.
67. Kitamura S, et al. (2015) Potent natural soluble epoxide hydrolase inhibitors from Pentadiplandra brazzeana baillon: Synthesis, quantification, and measurement of biological activities in vitro and in vivo. PLoS One 10(2): e0117438.
68. Yang J, Schmelzer K, Georgi K, Hammock BD (2009) Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 81(19): 8085-8093.
69. Ren Q, et al. (2015) BDNF-TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms. Transl Psychiatry 5: e666.